GlassScriptPhysician profile
Douglas Duvel
NPI 1275699811
$2,099.14
in general payments reported to CMS, 2019-2025
18 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $98.76 · 2021: $18.49 · 2022: $132 · 2023: $504 · 2024: $457 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,446.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $481.93 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $453.79 | 2019-2025 | |
| Abbvie INC. | $303.45 | 2019-2025 | Ubrelvy, Synthroid |
| Amgen INC. | $188.19 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $143.00 | 2019-2024 | Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $110.41 | 2019-2020 | |
| Myriad Women'S Health, INC. | $70.08 | 2023 | Myrisk |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.87 | 2023-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $47.27 | 2019-2025 | Zoryve |
| Merck Sharp & Dohme LLC | $42.44 | 2024 | Gardasil 9, Gardasil, Vaqta |
| Idorsia Pharmaceuticals US INC | $28.96 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $27.20 | 2019-2023 | |
| Exact Sciences Corporation | $26.73 | 2025 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $24.11 | 2025 | Aptima |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.92 | 2025 | Xifaxan |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $22.55 | 2019 | |
| Medtronic USA, INC. | $19.78 | 2019 | |
| Ibsa Pharma INC. | $17.46 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Duvel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.